These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 1998997)

  • 41. Determinants of acute regional toxicity following isolated limb perfusion for melanoma.
    Thompson JF; Eksborg S; Kam PC; Ingvar C; Yau DF; Lai DT; Ramzan I
    Melanoma Res; 1996 Jun; 6(3):267-71. PubMed ID: 8819130
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
    Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
    Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hyperthermic perfusion of recurrent malignant melanoma on the extremities.
    Hafström L; Jönsson PE
    Acta Chir Scand; 1980; 146(5):313-8. PubMed ID: 7468061
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
    Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
    J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumour response after hyperthermic isolated limb perfusion for locally advanced melanoma.
    Paulsen IF; Chakera AH; Drejøe JB; Klyver H; Dahlstrøm K; Oturai PS; Mortensen J; Hesse B; Schmidt G; Drzewiecki K
    Dan Med J; 2014 Jan; 61(1):A4741. PubMed ID: 24393586
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment.
    Hoekstra HJ; Schraffordt Koops H; de Vries LG; van Weerden TW; Oldhoff J
    Cancer; 1993 Aug; 72(4):1224-9. PubMed ID: 8393368
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of an automated circuit for isolated limb infusion for malignancy.
    Grobmyer SR; Filichia L; Robinson AR; Clark TD; Vaughn K; Copeland EM; Hochwald SN
    Eur J Surg Oncol; 2010 Dec; 36(12):1215-9. PubMed ID: 20947288
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Results of isolated lower limb perfusion for loco-regional advanced/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases.
    Pace M; Gattai R; Mascitelli EM; Millanta L
    J Surg Oncol; 2011 Dec; 104(7):718-23. PubMed ID: 21721008
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Surgical treatment and regional chemotherapy in melanoma of the extremities].
    Henneking K; Binder J; Weyers W; Schwemmle K
    Chirurg; 1993 Feb; 64(2):134-8. PubMed ID: 8462350
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systemic effects of hyperthermic isolated lower limb perfusion with carboplatin and interferon-beta.
    Tominaga R; Nakano T; Shibata S; Siraishi K; Nagae S; Nakayama J; Yasui H
    Artif Organs; 2001 Jan; 25(1):36-41. PubMed ID: 11167557
    [TBL] [Abstract][Full Text] [Related]  

  • 51. True versus mild hyperthermia during isolated hepatic perfusion: effects on melphalan pharmacokinetics and liver function.
    Pilati P; Mocellin S; Rossi CR; Ori C; Innocente F; Scalerta R; Ceccherini M; Da Pian PP; Nitti D; Lise M
    World J Surg; 2004 Aug; 28(8):775-81. PubMed ID: 15457357
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.
    Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS
    J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas].
    Alegre JF; Duarte M; Sureda González M; Bretcha Boix P; Dussan C; Ballester A; Crespo A; Brugarolas Masllorens A
    Cir Esp; 2012 Feb; 90(2):114-20. PubMed ID: 22225611
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Technic of isolated perfusion of the extremities. Experience with 171 cases].
    Aigner K; Schwemmle K
    Langenbecks Arch Chir; 1983; 359(2):113-22. PubMed ID: 6681855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Isolated hyperthermic perfusion with mitoxantrone of melphalan in malignant melanoma of the limb.
    Huber R; Krüger I; Kuper K; Huber PM; Pichlmaier H
    Am J Surg; 1995 Oct; 170(4):345-52. PubMed ID: 7573726
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Technique and results of regional hyperthermic cytostatic arm perfusion for malignant melanoma.
    Würl P; Eichfeld U; Pauer HD; Gläser A; Rose U; Dralle H
    Surg Today; 1997; 27(8):719-25. PubMed ID: 9306586
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Isolated limb perfusion for melanoma.
    Kroon BB; Noorda EM; Vrouenraets BC; van Slooten GW; Nieweg OE
    Surg Oncol Clin N Am; 2008 Oct; 17(4):785-94, viii-ix. PubMed ID: 18722918
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Hyperthermic-antiblastic isolation perfusion for advanced melanoma of the limbs. The technic, immediate results and a review of the literature].
    Decian F; Balletto N; Camerini G; Depaoli M; D'Aniello R; Ameri A; Brisighella A; Bonalumi U; Bachi V; Civalleri D
    Minerva Chir; 1990 Oct; 45(19):1227-37. PubMed ID: 2074944
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Desflurane as a marker of limb-to-systemic leak during hyperthermic isolated limb perfusion.
    Stanley G; Sundarakumaran R; Crowley R; Kavanah M
    Anesthesiology; 2000 Aug; 93(2):574-6. PubMed ID: 10910485
    [No Abstract]   [Full Text] [Related]  

  • 60. Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma.
    Clark J; Grabs AJ; Parsons PG; Smithers BM; Addison RS; Roberts MS
    Melanoma Res; 1994 Dec; 4(6):365-70. PubMed ID: 7703715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.